Extracorporeal granulocyte adsorption treatment of patients with rheumatoid arthritis using a cellulose acetate beads (G-1 column).

禮司, 粕川; 槇一, 吉野; 守弘, 大原; 十郎, 藤森; 昭, 岡野; 美津夫, 清水; 英光, 江澤; 和彦, 江澤; 鉄三, 阿岸

doi:10.2492/jsir1981.14.239

Cited by 3 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The velocity of perfusion is 30 ml/ min, and the duration of 1 treatment is 60 min (Fig. 2) [16,17]. In a standard protocol, perfusion is performed once a week for 4 weeks, but some patients in the clinical trials were treated twice a week for 4 weeks.…”

Section: The G-1 Columnmentioning

confidence: 99%

See 1 more Smart Citation

Clinical and basic studies on the G-1 column, a new extracorporeal therapeutic device effective in controlling rheumatoid arthritis

Kyogoku

Kasukawa

1998

Inflammation Research

View full text Add to dashboard Cite

The G-1 column, which is filled with cellulose acetate spherical beads of 2 mm diameter, is a new type of extracorporeal perfusion device originally designed to remove granulocytes from the venous circulation of patients with rheumatoid arthritis. A dramatic improvement in clinical symptoms was seen after treatment with the G-1 column in two successive clinical trials. Early effects include pain relief, reduction in the swollen joints, and a continued decrease in inflammation as a late effect. The results were further confirmed in the adjuvant arthritic rat model. G-1 beads adsorb some amounts of platelets at the beginning and then about a quarter of circulating neutrophils, monocytes, natural killer cells, and B cells, but not T cells. Various factors released from blood cells during transit through the column must have influenced the cells including lymphocytes which passed through the column. G-column actually eliminates some parts of aggressive leukocytes, but a more interesting story is the modification of blood components, which occurred in the G-1 column, and when returned to the patients, may have ameliorated the unbalanced homeostatic network and induced acceleration of healing.

show abstract

Section: The G-1 Columnmentioning

confidence: 99%

“…The first preliminary clinical trial of G-1 treatment was performed on 40 patients with rheumatoid arthritis, at 4 hospitals [16]. Clinical symptoms were ameliorated immediately after the start of treatment, and continued to improve for 4 weeks.…”

Section: Clinical Studies On G-1mentioning

confidence: 99%

Clinical and basic studies on the G-1 column, a new extracorporeal therapeutic device effective in controlling rheumatoid arthritis

Kyogoku

Kasukawa

1998

Inflammation Research

View full text Add to dashboard Cite

show abstract

“…The G-1 column was designed to adsorb adherent populations of leukocytes from the bloodstream. In fact, it has been demonstrated that apheretic therapy with the G-1 column results in marked clinical improvement in patients suffering from various intractable inflammatory diseases, such as ulcerative colitis [2][3][4] and rheumatoid arthritis [5][6][7][8][9][10][11][12][13][14] and even acquired immune deficiency syndrome (AIDS). 15 In animal models, G-1 column treatment decreased the severity of adjuvant arthritis in rats [12][13][14] and in a rabbit model for Glynn's arthritis.…”

Section: Introductionmentioning

confidence: 99%

Effect of G-1 column (Adacolumn) therapy in rats with adjuvant arthritis on the migration and immunoreactivity of peripheral and splenic leukocytes

et al. 2005

View full text Add to dashboard Cite

The G-1 column (Adacolumn), a novel extracorporeal adsorption device, is now available for the treatment of such chronic inflammatory diseases as ulcerative colitis and rheumatoid arthritis. G-1 column treatment sometimes results in a rapid decrease in clinical inflammatory parameters and/or has a delayed beneficial effect on disease activity. In order to identify the scientific basis for such clinical benefits, we studied rats with adjuvant arthritis induced by immunization with Mycobacterium butyricum antigen. The potential role of G-1 column treatment on the migratory properties and immunoreactivities of leukocytes was investigated. Treatment of arthritic rats for 60 min with an extracorporeal perfusion through the G-1 column led to the adsorption of a small proportion (20%) of circulating granulocytes and monocytes. However, after G-1 treatment, the migration of radiolabeled blood granulocytes and monocytes to sites of acute dermal inflammatory reactions decreased significantly, in the case of granulocytes, almost by half. The migration of granulocytes to the inflamed hindpaws of severely affected animals was diminished in the G-1 treated group. Granulocytes that have passed through the G-1 column may stay in the bloodstream because of their markedly diminished number of adhesion molecules. A slightly increased accumulation in the liver and a decreased localization in the lung was also observed. These results may be relevant to the rapid clinical anti-inflammatory effect observed in rheumatoid arthritis and possibly also in ulcerative colitis, without any pulmonary complications. In contrast, the adsorption rate by the G-1 column of T lymphocytes was very low, and their migration pattern to sites of dermal inflammatory reactions was not altered after treatment. However, the antigen (Mycobacterium purified protein derivative) reactivity of T lymphocytes in blood was almost completely abolished after G-1 column treatment of arthritic rats. This unexpected qualitative effect on T lymphocytes of G-1 treatment warrants further detailed study.

show abstract

“…Granulocytapheresis using a G-1 column is usually performed weekly for 4 weeks as an intensive therapy and monthly for 6 months as a maintenance therapy. During each session 1,800 ml of whole blood is treated at a flow rate of 30 ml for 1 h. Approximately, 5 x 10' of granulocytes and 1 x 10' of lymphocytes can be removed during a granulocytapheresis session (9). Cryofiltration removes cryogel that contains various types of macromolecules including cryoproteins, immunoglobulins, immune complexes, complement, etc.…”

mentioning

confidence: 99%

Current Therapeutic Apheresis Technologies for Inflammatory Bowel Disease

Yatnaji

Fukunaga

Yamane

et al. 1998

Therapeutic Apheresis

View full text Add to dashboard Cite

A large number of physicians have indicated that patients with inflammatory bowel diseases (IBD) such as ulcerative colitis (UC) and Crohn's disease (CD) respond to current apheresis technology treatment. However, the mechanism of the apheresis procedure is undefined for patients with IBD. IBD appears to be caused by a complex of interactions from the genes, environment, and the immune system; therefore, the immune system plays a crucial role in the inflammatory responses. In this process, lots of interactions occur simultaneously, and they cross relate with each other. This review paper briefly discusses the etiology and pathogenesis of IBD and attempts to elucidate the mechanism that occurs after apheresis treatment.

show abstract

Extracorporeal granulocyte adsorption treatment of patients with rheumatoid arthritis using a cellulose acetate beads (G-1 column).

Cited by 3 publications

References 13 publications

Clinical and basic studies on the G-1 column, a new extracorporeal therapeutic device effective in controlling rheumatoid arthritis

Clinical and basic studies on the G-1 column, a new extracorporeal therapeutic device effective in controlling rheumatoid arthritis

Effect of G-1 column (Adacolumn) therapy in rats with adjuvant arthritis on the migration and immunoreactivity of peripheral and splenic leukocytes

Current Therapeutic Apheresis Technologies for Inflammatory Bowel Disease

Contact Info

Product

Resources

About